CPC C07J 9/005 (2013.01) [A61P 1/16 (2018.01); A61P 3/08 (2018.01); C07J 41/00 (2013.01); C07J 41/0061 (2013.01); C07J 43/003 (2013.01)] | 15 Claims |
1. A method of treating a metabolic disease or disorder in a subject, comprising administering to the subject in need thereof a therapeutically effective amount of a compound of formula A:
or a pharmaceutically acceptable salt, solvate, ester, tautomer, amino acid conjugate, or metabolite thereof, wherein:
A is
oxadiazolonyl, or isoxazolonyl, wherein the carbon atom marked with “*” is bonded to the carbon atom to which A is bonded;
n is 0, 1, or 2;
R1 is H or OH;
R2 is H or OH;
R3 is CR11R12C(O)OH, C(O)NHR31, tetrazolyl, oxadiazolyl, oxadiazolonyl, or thiazolidine-dionyl optionally substituted with NHS(O)2—(C1-C3) alkyl;
R11 and R12 are each independently H, F, OH, CH2OH, or CH2F, provided that Ru and R12 are not both H;
R31 OH, (CH2)pOH, or (CH2)pOSO3H; and
p is 1 or 2,
wherein the metabolic disease or disorder is selected from obesity, diabetes, diabesity, metabolic syndrome, insulin resistance, including pre-diabetic insulin resistance, hypertension, and dyslipidemia.
|